IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions of 100.00% for the 12-month period ending 2014-03-31, per its 10-K filed 2014-07-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions · last filed 2014-07-15
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for the quarter ending 2011-06-30 was 100.00%.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for fiscal 2014 was 100.00%, a 0.00% change from fiscal 2013.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for fiscal 2013 was 100.00%.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for fiscal 2009 was 100.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 12 month |
|---|---|---|
| 2014-03-31 | 100.00% 10-K · filed 2014-07-15 | |
| 2013-03-31 | 100.00% 10-K · filed 2014-07-15 | |
| 2011-06-30 | 100.00% 10-K · filed 2014-07-15 | |
| 2009-12-31 | 100.00% 10-K · filed 2014-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |